Thus, a molecule which exhibits selectivity towards normal and cancer breast cells could find a potential application as a strategy to lower the Nrf2 level and improve current breast cancer therapies, or as could be proposed for SFN based on the literature data, as a strategy to increase the detoxification system of normal cells with no effect on cancer tissue, which in turn could mitigate the toxic effects of therapeutics. Here, NFE2L2 is linked to breast cancer.